|
1
|
Paijens ST, Vledder A, de Bruyn M and
Nijman HW: Tumor-infiltrating lymphocytes in the immunotherapy era.
Cell Mol Immunol. 18:842–859. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanahan D and Coussens LM: Accessories to
the crime: Functions of cells recruited to the tumor
microenvironment. Cancer Cell. 21:309–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim TK, Vandsemb EN, Herbst RS and Chen L:
Adaptive immune resistance at the tumour site: Mechanisms and
therapeutic opportunities. Nat Rev Drug Discov. 21:529–540. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duan Q, Zhang H, Zheng J and Zhang L:
Turning cold into hot: Firing up the Tumor Microenvironment. Trends
Cancer. 6:605–618. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang
Y and Li X: Exploring immunotherapy in colorectal cancer. J Hematol
Oncol. 15:952022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
André T, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab in Microsatellite-Instability-High advanced
colorectal cancer. N Engl J Med. 383:2207–2218. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Casak SJ, Marcus L, Fashoyin-Aje L, Mushti
SL, Cheng J, Shen YL, Pierce WF, Her L, Goldberg KB, Theoret MR, et
al: FDA approval summary: Pembrolizumab for the First-line
treatment of patients with MSI-H/dMMR advanced unresectable or
metastatic colorectal carcinoma. Clin Cancer Res. 27:4680–4684.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ganesh K: Optimizing immunotherapy for
colorectal cancer. Nat Rev Gastroenterol Hepatol. 19:93–94. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Keum N and Giovannucci E: Global burden of
colorectal cancer: Emerging trends, risk factors and prevention
strategies. Nat Rev Gastroenterol Hepatol. 16:713–732. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li J, Ma X, Chakravarti D, Shalapour S and
DePinho RA: Genetic and biological hallmarks of colorectal cancer.
Genes Dev. 35:787–820. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y and Zhang Z: The history and
advances in cancer immunotherapy: Understanding the characteristics
of tumor-infiltrating immune cells and their therapeutic
implications. Cell Mol Immunol. 17:807–821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kao KC, Vilbois S, Tsai CH and Ho PC:
Metabolic communication in the tumour-immune microenvironment. Nat
Cell Biol. 24:1574–1583. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan TA, Yarchoan M, Jaffee E, Swanton C,
Quezada SA, Stenzinger A and Peters S: Development of tumor
mutation burden as an immunotherapy biomarker: Utility for the
oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McGrail DJ, Pilié PG, Rashid NU, Voorwerk
L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, et
al: High tumor mutation burden fails to predict immune checkpoint
blockade response across all cancer types. Ann Oncol. 32:661–672.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Havel JJ, Chowell D and Chan TA: The
evolving landscape of biomarkers for checkpoint inhibitor
immunotherapy. Nat Rev Cancer. 19:133–150. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang J, Huang D, Saw PE and Song E:
Turning cold tumors hot: From molecular mechanisms to clinical
applications. Trends Immunol. 43:523–545. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Galon J and Bruni D: Approaches to treat
immune hot, altered and cold tumours with combination
immunotherapies. Nat Rev Drug Discov. 18:197–218. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Westcott PMK, Sacks NJ, Schenkel JM, Ely
ZA, Smith O, Hauck H, Jaeger AM, Zhang D, Backlund CM, Beytagh MC,
et al: Low neoantigen expression and poor T-cell priming underlie
early immune escape in colorectal cancer. Nat Cancer. 2:1071–1085.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gettinger S, Choi J, Hastings K, Truini A,
Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, et al:
Impaired HLA class I antigen processing and presentation as a
mechanism of acquired resistance to immune checkpoint inhibitors in
lung cancer. Cancer Discov. 7:1420–1435. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamamoto K, Venida A, Yano J, Biancur DE,
Kakiuchi M, Gupta S, Sohn ASW, Mukhopadhyay S, Lin EY, Parker SJ,
et al: Autophagy promotes immune evasion of pancreatic cancer by
degrading MHC-I. Nature. 581:100–105. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Burr ML, Sparbier CE, Chan KL, Chan YC,
Kersbergen A, Lam EYN, Azidis-Yates E, Vassiliadis D, Bell CC,
Gilan O, et al: An Evolutionarily conserved function of polycomb
silences the MHC class I antigen presentation pathway and enables
immune evasion in cancer. Cancer cell. 36:385–401.e8. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Spranger S, Dai D, Horton B and Gajewski
TF: Tumor-residing batf3 dendritic cells are required for effector
T cell trafficking and adoptive T cell therapy. Cancer Cell.
31:711–723.e4. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wculek SK, Cueto FJ, Mujal AM, Melero I,
Krummel MF and Sancho D: Dendritic cells in cancer immunology and
immunotherapy. Nat Rev Immunol. 20:7–24. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hegde S, Krisnawan VE, Herzog BH, Zuo C,
Breden MA, Knolhoff BL, Hogg GD, Tang JP, Baer JM, Mpoy C, et al:
Dendritic cell paucity leads to dysfunctional immune surveillance
in pancreatic cancer. Cancer Cell. 37:289–307.e9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu YT and Sun ZJ: Turning cold tumors
into hot tumors by improving T-cell infiltration. Theranostics.
11:5365–5386. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Spranger S, Bao R and Gajewski TF:
Melanoma-intrinsic β-catenin signalling prevents anti-tumour
immunity. Nature. 523:231–235. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grasso CS, Giannakis M, Wells DK, Hamada
T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, et
al: Genetic mechanisms of immune evasion in colorectal cancer.
Cancer Discov. 8:730–749. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dangaj D, Bruand M, Grimm AJ, Ronet C,
Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL,
Benencia F, et al: Cooperation between constitutive and inducible
chemokines enables T cell engraftment and immune attack in solid
tumors. Cancer Cell. 35:885–900.e10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Apte RS, Chen DS and Ferrara N: VEGF in
signaling and disease: Beyond discovery and development. Cell.
176:1248–1264. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feig C, Jones JO, Kraman M, Wells RJ,
Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL,
et al: Targeting CXCL12 from FAP-expressing carcinoma-associated
fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic
cancer. Proc Natl Acad Sci USA. 110:20212–20217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sahai E, Astsaturov I, Cukierman E,
DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR,
Hunter T, et al: A framework for advancing our understanding of
cancer-associated fibroblasts. Nat Rev Cancer. 20:174–186. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McAndrews KM, Chen Y, Darpolor JK, Zheng
X, Yang S, Carstens JL, Li B, Wang H, Miyake T, Correa de Sampaio
P, et al: Identification of functional heterogeneity of
Carcinoma-Associated fibroblasts with distinct IL6-Mediated therapy
resistance in pancreatic cancer. Cancer Discov. 12:1580–1597. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Visser KE and Joyce JA: The evolving
tumor microenvironment: From cancer initiation to metastatic
outgrowth. Cancer Cell. 41:374–403. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tang J, Yan T, Bao Y, Shen C, Yu C, Zhu X,
Tian X, Guo F, Liang Q, Liu Q, et al: LncRNA GLCC1 promotes
colorectal carcinogenesis and glucose metabolism by stabilizing
c-Myc. Nat Commun. 10:34992019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM
and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li J, Guo BC, Sun LR, Wang JW, Fu XH,
Zhang SZ, Poston G and Ding KF: TNM staging of colorectal cancer
should be reconsidered by T stage weighting. World J Gastroenterol.
20:5104–5112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guo T, Kouvonen P, Koh CC, Gillet LC,
Wolski WE, Röst HL, Rosenberger G, Collins BC, Blum LC, Gillessen
S, et al: Rapid mass spectrometric conversion of tissue biopsy
samples into permanent quantitative digital proteome maps. Nat Med.
21:407–413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cai X, Xue Z, Wu C, Sun R, Qian L, Yue L,
Ge W, Yi X, Liu W, Chen C, et al: High-throughput proteomic sample
preparation using pressure cycling technology. Nat Protoc.
17:2307–2325. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun Y, Selvarajan S, Zang Z, Liu W, Zhu Y,
Zhang H, Chen W, Chen H, Li L, Cai X, et al: Artificial
intelligence defines protein-based classification of thyroid
nodules. Cell Discov. 8:852022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Demichev V, Messner CB, Vernardis SI,
Lilley KS and Ralser M: DIA-NN: Neural networks and interference
correction enable deep proteome coverage in high throughput. Nat
Methods. 17:41–44. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: A new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Amin MB, Edge SB, Greene FL, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. Springer
International Publishing; New York, NY: 2017
|
|
44
|
Bruni D, Angell HK and Galon J: The immune
contexture and Immunoscore in cancer prognosis and therapeutic
efficacy. Nat Rev Cancer. 20:662–680. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kenswil KJG, Pisterzi P, Sánchez-Duffhues
G, van Dijk C, Lolli A, Knuth C, Vanchin B, Jaramillo AC,
Hoogenboezem RM, Sanders MA, et al: Endothelium-derived stromal
cells contribute to hematopoietic bone marrow niche formation. Cell
Stem Cell. 28:653–670.e11. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Valkenburg KC, de Groot AE and Pienta KJ:
Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin
Oncol. 15:366–381. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yuan J, Li J, Gao C, Jiang C, Xiang Z and
Wu J: Immunotherapies catering to the unmet medical need of cold
colorectal cancer. Front Immunol. 13:10221902022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen EX, Jonker DJ, Loree JM, He Y, Zhang
Y, Hao C, Zeng P, Zhang M, Gao Y, Yang D, et al: Effect of combined
immune checkpoint inhibition vs best supportive care alone in
patients with advanced colorectal cancer: The Canadian cancer
trials group CO.26 Study. JAMA Oncol. 6:831–838. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li H, Wang X, Huang X, He Y, Zhang Y, Hao
C, Zeng P, Zhang M, Gao Y, Yang D, et al: Circulating glycan
monosaccharide composite-based biomarker diagnoses colorectal
cancer at early stages and predicts prognosis. Front Oncol.
12:8520442022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lin XT, Wu QN, Qin S, Fan DJ, Lv MY, Chen
X, Cai JW, Weng JR, Zou YF, Rong YM and Gao F: Identification of an
Autophagy-Related gene signature for the prediction of prognosis in
early-stage colorectal cancer. Front Genet. 12:7557892021.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ke J, Liu X-H, Jiang X-F, He Z, Xiao J,
Zheng B, Chen Y-F, Cai Z-R, Zheng X-B, Zou Y-F, et al:
Immune-related gene signature in predicting prognosis of
early-stage colorectal cancer patients. Eur J Surg Oncol.
46:e62–e70. 2020. View Article : Google Scholar : PubMed/NCBI
|
